Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Wilson Disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson Disease pipeline landscape is provided which includes the disease overview and Wilson Disease treatment guidelines. The assessment part of the report embraces, in depth Wilson Disease commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wilson Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Wilson Disease R&D. The therapies under development are focused on novel approaches to treat/improve Wilson Disease.
Wilson Disease Emerging Drugs Chapters
This segment of the Wilson Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Wilson Disease Emerging Drugs
VTX 801: Vivet Therapeutics
VTX-801 is a novel, investigational rAAV-based gene therapy vector designed to deliver a miniaturized ATP7B transgene encoding, a functional protein that has been shown to restore copper homeostasis, reverse liver pathology and reduce copper accumulation in the brain of a mouse model of Wilson Disease. VTX-801's rAAV serotype was selected based on its demonstrated tropism for transducing human liver cells. VTX-801 is a novel investigational gene therapy for Wilson Disease, which has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) and the European Commission (EC) and Fast Track designation by the FDA. Currently, the drug is in the Phase I/II stage of its development for the treatment of Wilson Disease
Wilson Disease: Therapeutic Assessment
Major Players in Wilson Disease
There are approx. 5+ key companies which are developing the therapies for Wilson Disease. The companies which have their Wilson Disease drug candidates in the most advanced stage, i.e. Phase I/II include, Vivet Therapeutics.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Wilson Disease drugs?
- How many Wilson Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wilson Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Wilson Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Wilson Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Vivet therapeutics
- Depymed Inc
- Prime Medicine
- Deep genomics
Key Products
- VTX-801
- DPM 1001
- Research programme hepatolenticular degeneration gene therapies
- DG 12P1
Phases
The report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Wilson Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Wilson Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wilson Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wilson Disease drugs.
Wilson Disease Report Insights
- Wilson Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Wilson Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/n3b62j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
